NACDS names new 2014-2015 officers
SCOTTSDALE, Ariz. — The National Association of Chain Drug Stores on Monday announced that it had elected new officers, one new executive committee member and three new board of directors members for the coming year during its annual meeting this weekend.
John Standley, chairman and CEO of Rite Aid, was elected as the new NACDS chairman of the board of directors. Standley succeeds Robert Narveson, president and CEO of Thrifty White Pharmacy. Additionally, Juan Ortiz, CEO Navarro Discount Pharmacies, was named vice chairman and Randall Edeker, chairman and CEO Hy-Vee, was elected treasurer.
“It is a pleasure to welcome John Standley as the new chairman of the NACDS Board of Directors,” said NACDS President and CEO Steven C. Anderson, IOM, CAE. “In his role as vice chairman of the board and chairman of the NACDS Political Action Committee, John has demonstrated leadership and a strong commitment to the industry and to NACDS.”
The NACDS board also elected Randall Edeker as a new executive committee member. Three new board of directors also were elected: Carmen Bauza, SVP and general merchandise manager, health and wellness for Walmart; Daniel Salemi, RPh, president of pharmacy division for New Albertsons; and J.K. Symancyk, president of Meijer.
Kimberly-Clark partners with Christina Milian for campaign
IRVING, TX — Kimberly-Clark has teamed up with Grammy-nominated singer-songwriter Christina Milian to launch an integrated Celebrate Family UNity ("FUN") platform that leverages social media to retain existing consumers and reach out to new ones.
An integral part of the program is the Family UNity ("FUN") Song web app where families can customize their own "FUN song," share it on social media and download it as a ringtone.
Now through July 20, people can visit TheFunSong.com to get their own custom FUN song by answering some questions to share about their family and picking a hip-hop, rock or Latin beat. The app then instantly composes a custom MP3 song about them to whichever beat they choose.
"The Kimberly-Clark Celebrate Family UNity program is a great way for all families to celebrate the unique bonds that only they share," Milian said. "Music is a universal language that connects families across all cultures, including my own, and it’s our goal to inspire more families to embrace their togetherness with the FUN program."
In California, residents who participate in the program by creating their own custom Family UNity (FUN) song will be entered for a chance to win a live recording session with Milian, where she will record her version of their family song. California consumers also will receive coupons for such Kimberly-Clark products as Huggies, Pull-Ups, U by Kotex, Kleenex and Scott, which will escalate in value as their FUN song is shared with others in social media — more shares mean more value on the coupons.
The program is being activated in California at Walmart, Target, Walgreens, Food4Less and Safeway stores.
"We’re excited to partner with Christina Milian to help elevate the Family UNity message through this new integrated program," said Lizette Williams, head of Kimberly-Clark’s multicultural strategy team and program lead. "The Celebrate FUN platform will truly allow Kimberly-Clark to be mom’s partner in her quest to keep her family together in a fun and innovative way. Our product portfolio has something for every member of the family — from Huggies diapers to Kleenex facial tissue."
Forest Labs set to acquire Furiex for $1.1 billion
NEW YORK & MORRISVILLE, N.C. — Forest Labs and Furiex Pharmaceuticals on Monday announced that Forest will acquire Furiex for $95 per share, or approximately $1.1 billion in cash.
Forest also announced that it has entered into an agreement with Royalty Pharma to sell Furiex’s royalties on alogliptin and Priligy to Royalty Pharma for approximately $415 million upon the completion of Forest’s acquisition of Furiex.
“The acquisition of Furiex builds on our growing position in gastroenterology and helps to create a leading GI company within Forest. It is a natural extension of our GI business following our $2.9 billion acquisition of Aptalis earlier this year,” said Brent Saunders, CEO and president of Forest Labs. “We believe eluxadoline will be very complementary to our anchor GI product Linzess and additive to our broader GI portfolio, making us more relevant to gastroenterologists and primary care physicians. With eluxadoline, we expect to have one of the broadest product offerings for the $38 billion GI disease market.”
Eluxadoline is a locally-acting mu opioid receptor agonist and a delta opioid receptor antagonist for treating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-d). IBS-d affects approximately 28 million patients in the United States and Europe, and Furiex is set to file a new drug application for the drug by the end of third-quarter 2014.